Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Virchows Arch ; 476(2): 331, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31707591

RESUMO

The name of the co-author of E-PS-07-008 (page S294) was presented as 'S. Despina' instead of 'D. Sgouridi' in the authorship group The name has been corrected in the authorship group shown above.

2.
Gene Ther ; 21(2): 158-67, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24285215

RESUMO

Lung cancer still remains to be challenged by novel treatment modalities. Novel locally targeted routes of administration are a methodology to enhance treatment and reduce side effects. Intratumoral gene therapy is a method for local treatment and could be used either in early-stage lung cancer before surgery or at advanced stages as palliative care. Novel non-viral vectors are also in demand for efficient gene transfection to target local cancer tissue and at the same time protect the normal tissue. In the current study, C57BL/6 mice were divided into three groups: (a) control, (b) intravenous and (c) intatumoral gene therapy. The novel 2-Diethylaminoethyl-Dextran Methyl Methacrylate Copolymer Non-Viral Vector (Ryujyu Science Corporation) was conjugated with plasmid pSicop53 from the company Addgene for the first time. The aim of the study was to evaluate the safety and efficacy of targeted gene therapy in a Lewis lung cancer model. Indeed, although the pharmacokinetics of the different administration modalities differs, the intratumoral administration presented increased survival and decreased distant metastasis. Intratumoral gene therapy could be considered as an efficient local therapy for lung cancer.


Assuntos
Antineoplásicos/efeitos adversos , Carcinoma Pulmonar de Lewis/terapia , DEAE-Dextrano/efeitos adversos , Metilmetacrilato/efeitos adversos , Metástase Neoplásica/terapia , Proteína Supressora de Tumor p53/metabolismo , Administração Intravenosa , Animais , Antineoplásicos/administração & dosagem , Carcinoma Pulmonar de Lewis/patologia , Linhagem Celular Tumoral , DEAE-Dextrano/administração & dosagem , Terapia Genética/efeitos adversos , Terapia Genética/métodos , Metilmetacrilato/administração & dosagem , Camundongos , Camundongos Endogâmicos C57BL , Plasmídeos/administração & dosagem
3.
Hippokratia ; 17(2): 180-2, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24376329

RESUMO

BACKGROUND: Primary malignant vascular tumors of bone are very rare accounting for less than 1% of primary bone malignancies. They are characterized by unknown etiology, variable biologic behavior and histological appearance. Angiosarcoma is an aggressive malignant vascular tumor derived from mesenchymal cells with endothelial differentiation. CASE REPORT: We present a rare case of angiosarcoma of bone in a 47-year-old male operated for a lumbar disk herniation. During his transportation from the operation theater, a pathological intertrochanteric fracture of the right hip occured. The magnetic resonance imaging (MRI) revealed a bone lytic lesion located into the great trochanter of the right femur. Open surgical biopsy of the lesion was performed and the histological examination showed primary angiosarcoma of bone. The treatment included radiotherapy (300 cGy per fraction in 13 days) followed by excision of the proximal femur and custom made total hip arthroplasty. The diagnosis was confirmed on the surgical specimen.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA